These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 34425871)
1. Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871 [TBL] [Abstract][Full Text] [Related]
2. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA; J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Woolf DK; Beresford M; Li SP; Dowsett M; Sanghera B; Wong WL; Sonoda L; Detre S; Amin V; Ah-See ML; Miles D; Makris A Br J Cancer; 2014 Jun; 110(12):2847-54. PubMed ID: 24832174 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810 [TBL] [Abstract][Full Text] [Related]
5. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients. Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355 [TBL] [Abstract][Full Text] [Related]
7. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT. Nakajo M; Nakajo M; Kajiya Y; Jinguji M; Nishimata N; Shimaoka S; Nihara T; Aridome K; Tanaka S; Fukukura Y; Tani A; Koriyama C Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1223-32. PubMed ID: 23653240 [TBL] [Abstract][Full Text] [Related]
11. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494 [TBL] [Abstract][Full Text] [Related]
12. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400 [TBL] [Abstract][Full Text] [Related]
13. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123 [TBL] [Abstract][Full Text] [Related]
14. Subtype-Guided Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448 [TBL] [Abstract][Full Text] [Related]
16. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
17. IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. Palmieri C; Szydlo R; Miller M; Barker L; Patel NH; Sasano H; Barwick T; Tam H; Hadjiminas D; Lee J; Shaaban A; Nicholas H; Coombes RC; Kenny LM Breast Cancer Res Treat; 2017 Nov; 166(2):527-539. PubMed ID: 28795252 [TBL] [Abstract][Full Text] [Related]
18. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma. Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118 [TBL] [Abstract][Full Text] [Related]
20. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]